Background: To assess the safety and efficacy of flush endovenous laser ablation (fEVLA) in the treatment of chronic venous insufficiency (CVI).
Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a systematic review aiming to identify studies published from inception to March 2024 was conducted. The investigation covered single-arm studies and studies comparing fEVLA to standard EVLA (sEVLA). The primary endpoint was endovenous heat-induced thrombosis (EHIT) class ≥ II.
Results: Eleven studies encompassing 2738 patients and 3147 truncal veins were included. The pooled EHIT ≥ II was 1.37% (95% CI: 0.57-3.28). Meta-regression identified an association between linear endovenous energy density (LEED) applied at the saphenofemoral junction (SFJ) and EHIT ≥ II outcomes (β = 0.011, P < 0.01). The pooled medium-term great saphenous vein (GSV) occlusion was 97.59% (95% CI: 94.89-98.88). The pooled and crude deep vein thrombosis (DVT) and pulmonary embolism (PE) estimates were 0.97% (95% CI: 0.64-1.47) and 0.04%. The comparative analysis regarding GSV occlusion, odds ratio (OR) 3.26 (95% CI: 0.76-13.97) and refluxing anterior accessory saphenous vein (AASV), risk ratio (RR) 0.45 (95% CI: 0.11-1.77) suggested a nonstatistically significant trend favoring fEVLA. Nonstatistically significant differences were identified in terms of EHIT ≥ II between the techniques, RR 1.00(95% CI: 0.18-5.53). Statistically significant differences favoring fEVLA were identified in terms of proximal groin recurrence RR 0.35 (95% CI: 0.16-0.80) and stump length (mean difference) MD -7.23 (95% CI: -11.59to-2.88).
Conclusion: This review has demonstrated the safety of fEVLA while also suggesting a potentially improved efficacy of fEVLA over sEVLA in terms of proximal groin recurrence. Moreover, the trend indicating fEVLA's superiority in terms of GSV occlusion and the occurrence of new-onset AASV reflux merits further research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.avsg.2024.12.041 | DOI Listing |
Eur J Vasc Endovasc Surg
January 2025
Department of Phlebology, Skin and Vein Clinic Oosterwal, Alkmaar, the Netherlands.
Objective: The aim of this study was to compare anterior accessory saphenous vein (AASV) reflux after standard endovenous laser ablation (EVLA) vs. flush EVLA (fEVLA) of the great saphenous vein (GSV).
Methods: This was as randomised, single blind, controlled trial (Dutch Trial Register, NL5283).
Ann Vasc Surg
December 2024
Department of Vascular Surgery, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece.
Background: To assess the safety and efficacy of flush endovenous laser ablation (fEVLA) in the treatment of chronic venous insufficiency (CVI).
Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a systematic review aiming to identify studies published from inception to March 2024 was conducted. The investigation covered single-arm studies and studies comparing fEVLA to standard EVLA (sEVLA).
J Clin Med
November 2024
Department of Vascular Surgery, Jun's Vascular Clinic, Busan 47256, Republic of Korea.
Blood flow from the saphenofemoral junction(SFJ) tributaries may cause recurrence of varicose veins. Flush occlusion is defined as the total occlusion of the great saphenous vein(GSV) right to the saphenofemoral junction. The purpose of this study was to evaluate the efficacy and safety of flush endovenous thermal ablation with saphenofemoral junction tributary occlusion.
View Article and Find Full Text PDFJ Clin Med
June 2023
Department of Vascular Surgery, Diakonie-Klinikum, 74523 Schwaebisch Hall, Germany.
Background: Heterogeneity regarding dosimetry and reporting of endovenous laser ablation (EVLA) mandates the development of a standardized protocol. This study presents the mid-term results of EVLA with 1940 nm-laser and radial-fibre, supported by a four-zone dosimetry tool.
Materials And Methods: Four anatomical dosimetry zones for great saphenous veins (GSV) and two for small saphenous veins (SSV) were defined with set power levels.
J Vasc Surg Venous Lymphat Disord
May 2023
Heart, Artery, and Vein Center of Fresno, Fresno, CA. Electronic address:
Objective: Postablation deep vein thrombosis (DVT) represents a potentially serious complication after Varithena polidocanol endovenous microfoam (PEM) ablation. The following primary outcomes were assessed: whether (1) adjunctive apixaban anticoagulation or (2) mechanical deep venous system (DVS) saline flushing could decrease saphenofemoral junction (SFJ) thrombus extension (postablation superficial thrombus extension [PASTE]) and/or DVT compared with compression alone, after great saphenous vein (GSV) PEM ablation.
Methods: Varithena 1% PEM ablation patients were randomized to (1) SFJ compression, (2) compression and DVS saline flushing, or (3) compression, DVS saline flushing, and 5 days of postprocedural 5 mg oral apixaban anticoagulation twice daily.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!